GLGuodong Li

Guodong Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Guodong Li has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Integrative metabolome and transcriptome profiling reveals discordant glycolysis process between osteosarcoma and normal osteoblastic cells

    by Kai Chen, Chunyan Zhu, Ming Cai, Dong Fu, Biao Cheng, Zhengdong Cai, Guodong Li, Jilong Liu

    Osteosarcoma (OS) is the most common primary malignant tumor of bone in children and adolescents. However, few biomarkers of diagnostic significance have been established. In recent years, high-throughput transcriptomic and metabolomic approaches make it possible for studying the levels of thousands of biomarkers simultaneously. In this study, we integrated two disparate transcriptomic and metabolomic datasets to find meaningful biomarkers and then used an independent dataset to test the sensibility and specificity of these biomarkers. By using integrated two datasets, we discovered that the biomarkers involved in the glycolysis pathway are highly enriched, including 4 genes (ENO1, TPI1, PKG1 and LDHC) and 2 metabolites (lactate and pyruvate). The 4 genes were significantly down-regulated in OS samples as well as the 2 metabolites. The mixed metabolites + genes signature also outperformed metabolites or genes alone, with recall being 0.813 and F-measure being 0.812. And the AUC value of metabolites + genes classifier was 0.825 (compared to 0.58 for metabolites and 0.821 for genes alone). Our findings establish that integrated transcriptomic and metabolomic signature can be used to distinguish OS malignant with good diagnostic accuracy superior to other methods.


  • Patellar resurfacing versus nonresurfacing in total knee arthroplasty: A meta-analysis of randomised controlled trials

    by Kai Chen, Guodong Li, Dong Fu, Chaoqun Yuan, Qiang Zhang, Zhengdong Cai

    Patella resurfacing or nonresurfacing in total knee arthroplasty remains controversial. The aim of this study was to evaluate the efficacy of patellar resurfacing through an evaluation of the current literature. We carried out a meta-analysis of randomised controlled trials comparing total knee arthroplasties performed with and without patellar resurfacing. Outcomes of reoperation, anterior knee pain and knee scores were analysed. Fourteen trials assessing 1,725 knees were eligible. The absolute risk of reoperation was reduced by 4 % (95 % confidence interval, 2–6 %) in the patellar resurfacing arm (between-study heterogeneity, P = 0.05, I2 = 42 %), implying that one would have to resurface 25 patellae (95 % confidence interval, 17–50 patellae) in order to prevent one reoperation. There was no difference between the two groups in terms of anterior knee pain, knee pain score, Knee Society score and knee function score. But in the studies followed up for a mean time of not less than five years, a difference was found between the two arms in Knee Society scores (RR = 2.14, 95 % confidence interval, 0.76–3.52; P = 0.002). The available evidence indicates that patellar resurfacing reduces the risk of reoperation after total knee arthroplasty. Patellar resurfacing patients may make a difference in long-term follow-up (five or more 5 years) of Knee Society scores. In other aspects, the benefit of patellar resurfacing is limited. Additionally, more carefully and scientifically designed randomised controlled trials are required to further prove the claim.


  • Surgical strategy for the management of sacral giant cell tumors: a 32-case series

    by Guodong Li, Dong Fu, Kai Chen, Xiaojun Ma, Mengxiong Sun, Wei Sun, Jian Li, Zhendong Cai


    • 1 November 2011
      • Vol. 33  (11) , 836-41

    [Screening of serum marker proteins in osteosarcoma and preliminary bioinformatic analysis on POLR3F].

    by Guo-Dong Li, Zheng-Dong Cai, Xiao-Jun Ma, Meng-Xiong Sun, Jian Li, Wei Sun, Ying-Qi Hua

    To screen potential serum marker proteins of osteosarcoma, and to make a preliminary bioinformatics analysis of RNA polymerase III polypeptide F (POLR3F). Gene chip and SELDI-TOF MS was used to screen genes differentially expressed in osteosarcoma. The associations of potential biomarkers from SELDI data and microarray analysis were further inferred by link-test to identify biomarkers that could likely be used for diagnosis. MATLAB was used to search transcription factors binding site in the promoter region and miRNAs binding site in 3'-UTR of POLR3F, respectively. 653 differentially expressed genes were found in osteosarcoma cells, while six differentially expressed protein peaks with significant statistical significances were detected by SELDI-TOF MS in patient's serum. 13 potential biomarkers for early diagnosis of osteosarcoma were screened by link-test. A conserved STAT3 binding site and a miRNA target site were found in proximal promoter regions and 3'-UTR region of POLR3F, respectively. Link-test is a effective method to identify osteosarcoma biomarkers from both microarray and SELDI-TOF MS database. The results confirmed that POLR3F may be a promising biomarker for early diagnosis and a therapy target of osteosarcoma.


  • Open Access

    An integrative multi-platform analysis for discovering biomarkers of osteosarcoma

    by Guodong Li, Wenjuan Zhang, Huazong Zeng, Lei Chen, Wenjing Wang, Jilong Liu, Zhiyu Zhang, Zhengdong Cai

    SELDI-TOF-MS (Surface Enhanced Laser Desorption/Ionization-Time of Flight-Mass Spectrometry) has become an attractive approach for cancer biomarker discovery due to its ability to resolve low mass proteins and high-throughput capability. However, the analytes from mass spectrometry are described only by their mass-to-charge ratio (m/z) values without further identification and annotation. To discover potential biomarkers for early diagnosis of osteosarcoma, we designed an integrative workflow combining data sets from both SELDI-TOF-MS and gene microarray analysis.